Cargando…
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), and nonfermenting Gram-negative bacilli, including Pseudomonas aerug...
Autores principales: | Rolston, Kenneth V. I., Gerges, Baghat, Shelburne, Samuel, Aitken, Samuel L., Raad, Issam, Prince, Randall A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179642/ https://www.ncbi.nlm.nih.gov/pubmed/32071053 http://dx.doi.org/10.1128/AAC.01955-19 |
Ejemplares similares
-
1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients
por: Rolston, Kenneth V I, et al.
Publicado: (2018) -
In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer
por: Rolston, Kenneth, et al.
Publicado: (2023) -
The in vitro activity of delafloxacin and comparator agents against bacterial pathogens isolated from patients with cancer
por: Gerges, Bahgat, et al.
Publicado: (2023) -
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
por: Mushtaq, Shazad, et al.
Publicado: (2020) -
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
por: Hackel, Meredith A., et al.
Publicado: (2018)